Veradigm Inc
Over The Counter Market:MDRX

  • LAST PRICE
    8.7500
  • TODAY'S CHANGE (%)
    1.1998 (15.8910%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    7.6000 / 7.5502
  • Day Range
    7.6000
    8.8000
  • 52 Week Range
    5.0100
    14.0900
  • Volume
    5,134,105

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Today

      Show headlines and story abstract

    • 5 hours ago by Dow Jones
      Companies Mentioned: MDRX

      Ratings actions from Benzinga: https://www.benzinga.com/quote/MDRX/analyst-ratings

      (END) Dow Jones Newswires

      May 28, 2024 11:50 ET (15:50 GMT)

    • 10 hours ago by Business Wire
      Companies Mentioned: MDRX

      Veradigm Inc. (OTCMKTS: MDRX, the "Company"), a leading provider of healthcare data and technology solutions, today announced that it has initiated a process to explore strategic alternatives to maximize shareholder value.

    • 10 hours ago by Business Wire
      Companies Mentioned: MDRX

      --Interim CFO Lee Westerfield extends term with Company

      Veradigm Inc. (OTCMKTS: MDRX, the "Company"), a leading provider of healthcare data and technology solutions, today announced that, on June 7, 2024, Tom Langan, the Company's President and Chief Commercial Officer (CCO), will assume the role of interim Chief Executive Officer (CEO), reporting directly to the Executive Chairman and the Board. Mr. Langan has been a Company leader since 2018 and has more than 25 years of life sciences, payer and data & analytics experience. Interim Chief Financial Officer (CFO) Lee Westerfield, who joined Veradigm in December 2023 after more than 25 years of experience as a senior financial executive, has agreed to extend his term of service with the Company through December 31, 2024. The current interim CEO, Dr. Yin Ho, will step down following the expiration of her term of service on June 7, 2024. The Company does not plan to make any permanent executive appointments while the separately announced exploration of strategic alternatives is in process.

  • May 24, 2024

Peers Headlines